Wound care company Sanuwave Health announced that it entered into a business combination agreement with SEP Acquisition Corp. The merger with SEP, a special purpose acquisition company (SPAC), aims to create a Nasdaq-listed company. Upon the transaction’s completion, the combined company expects to operate under the Sanuwave name and the “SNWV” ticker. The proposed transaction […]
SANUWAVE Health Inc.
Sanuwave completes Celarity buy
Sanuwave Health (OTC:SNWV) announced that it completed its acquisition of Celularity’s UltraMist ultrasound healing therapy platform. In June, the companies announced an exclusive agreement for the purchase, which includes exclusive partnership rights for Celularity’s wound care biologic products. Celularity develops allogeneic cellular therapies engineered from postpartum human placenta, in cancer, infectious disease and degenerative disease. Along with the […]
Sanuwave announces intent to acquire Celularity’s UltraMist
Sanuwave Health (OTC:SNWV) announced that it entered into an exclusive agreement to acquire Celularity’s UltraMist ultrasound healing therapy platform. The non-binding letter of intent includes the acquisition of UltraMist and exclusive partnership rights for Celularity’s wound care biologic products, according to a news release. Celularity develops allogeneic cellular therapies engineered from postpartum human placenta, in cancer, […]
Sanuwave partners with The Mobile Health Company
Sanuwave Health announced that it is partnering with its former president’s new business, The Mobile Health Company (MHC). Former Sanuwave president Shri Parikh launched MHC as a mobile solution for wound care and other treatments to be streamlined directly to a patient’s home setting. In launching MHC, Shri is resigning from Sanuwave, but will remain […]
Sanuwave Health, HyperMed partner for DermaPace diabetic foot ulcer study
Sanuwave Health (OTC:SNWV) said yesterday it is partnering with HyperMed to sponsor a clinical investigation exploring Sanuwave’s DermaPace system designed for treating diabetic foot ulcers. The joint study will look to quantify the level of increased perfusion and oxygenation during and after treatment with the DermaPace, Suwanee, Ga.-based Sanuwave said. The study will use HyperMed’s Hyperview […]
7 medtech stories we missed this week: July 21, 2017
From Second Sight’s South Korean market entry to Sanuwave’s Indonesian distribution deal, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Second Sight enters South Korea market Second Sight announced in a July 5 press release that it has entered the market in South Korea with the implantation […]
Sanuwave Health inks dev deal with eKare for wound care integration
Sanuwave Health (OTC:SNWV) said today it entered a memorandum of understanding with eKare to develop novel wound care analysis and management solutions which integrates technology from both companies. Through the deal, Sanuwave’s dermaPace wound treatment device will be linked with eKare’s inSight 3D wound imaging and analytics system to produce a comprehensive wound management solution, […]
Sanuwave Health taps Lithomed as Taiwanese ortho distributor
Sanuwave Health (OTC:SNWV) said today it tapped Lithomed as its orthopedic product distributor in Taiwan. Suwanee, Ga.-based Sanuwave said the selection of Lithomed was the result of an extensive search in the region, and that the contract comes with a minimum order value of $500,000. “Sanuwave has committed to deliver 3-5 new distribution partners in the second […]
Teleflex CEO Smith to step down | Personnel Moves | March 1, 2017
Teleflex (NYSE:TFX) said this month that CEO Benson Smith will retire from the corner office by the end of this calendar year. Smith will continue to serve as the company’s chairman of the board. Liam Kelly, president & chief operating officer, was tapped to succeed Smith as CEO for the Wayne, Pa.-based company. “I want to […]
Sanuwave files for de novo FDA nod for DermaPace wound care device
Sanuwave Health (OTC:SNWV) said last Thursday it filed a de novo petition with the FDA as it seeks approval for its DermaPace system designed for treating diabetic foot ulcers. Sanuwave said it expects to hear a response from the FDA within 120 days, and is hopeful that evidence from over 336 patients across 2 trials are enough […]
Sanuwave trial misses efficacy endpoint but shows superiority at 24 weeks
Sanuwave Health (OTC:SNWV) today released 24-week data from the pivotal trial of its dermaPace, saying it missed its 12-week primary efficacy endpoint but returned a greater reduction in wound size and lowered amounts of subjects with increased wound size compared to the control treatment at 24 weeks. Data came from 2 24-week studies at 39 centers across the […]
